ReNeuron Group (RENE)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 3.38p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 11.13p
  • 52 Week Low: 3.38p
  • Currency: UK Pounds
  • Shares Issued: 57.17m
  • Volume: 0
  • Market Cap: £1.93m
  • RiskGrade: 394

ReNeuron treats first Oxford patient as part of expanded study

By Josh White

Date: Monday 18 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.
The AIM-traded firm said the remaining study subjects were expected to be treated by the end of 2021.

It explained that its hRPC therapeutic candidate was undergoing phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP), which affects 1 in 4,000 people in the United States and worldwide.

The expanded study encompassed four sites worldwide, with two sites in the US as well as the recently-activated sites in the UK and in Spain.

ReNeuron saud the study used a cryopreserved human retinal progenitor cell line (hRPC) formulation, enrolling subjects with advanced RP with some remaining central vision.

The two million cell dose used in the study extension represented a doubling of the earlier dose level, where good product safety and efficacy signals were seen in subjects followed out to 12 months.

As it previously announced, the company was expecting to present early efficacy data from the extension segment of the study in the first quarter of 2022.

ReNeuron said it was on track to advance the programme into the next clinical trial by the end of 2022.

"We are extremely pleased to see the first subject dosed in the UK in this phase 2a clinical evaluation for our hRPC therapeutic candidate and expect to complete dosing of the remaining subjects in the expanded segment of the study by the end of 2021," said chief executive officer Olav Hellebø.

"We are proud to be working with the University of Oxford, a team globally renowned for cutting edge retinal disease research.

"We look forward to updating the market in the first quarter of next year on early efficacy data from the expanded phase 2a study."

At 0840 BST, shares in ReNeuron Group were up 1.72% at 118.5p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

ReNeuron Group Market Data

Currency UK Pounds
Share Price 3.38p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 11.13p
52 Week Low 3.38p
Volume 0
Shares Issued 57.17m
Market Cap £1.93m
RiskGrade 394

ReNeuron Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
68.30% above the market average68.30% above the market average68.30% above the market average68.30% above the market average68.30% above the market average
18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average18.52% above the sector average
Price Trend
90.17% below the market average90.17% below the market average90.17% below the market average90.17% below the market average90.17% below the market average
71.93% below the sector average71.93% below the sector average71.93% below the sector average71.93% below the sector average71.93% below the sector average
Income Not Available
Growth
4.82% above the market average4.82% above the market average4.82% above the market average4.82% above the market average4.82% above the market average
2.70% above the sector average2.70% above the sector average2.70% above the sector average2.70% above the sector average2.70% above the sector average

ReNeuron Group Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Top of Page